THERALOGICS, INC.

Company Information
Address P.O.Box 12613
Research Triangle Park
Durham, NC, -


Information

DUNS: 170945617

# of Employees: 2


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Validation of a Novel NF-kB Inhibitor in Inflammatory Bowel Disease

    Amount: $1,396,256.00

    DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, affect over one million Americans and significant unmet medical needs sti ...

    STTRPhase II2012Department of Health and Human Services
  2. Evaluation of NBD Peptides as an Adjunct Therapy for the Treatment of Non-Hodgkin

    Amount: $420,475.00

    DESCRIPTION (provided by applicant): The NF-?B family of transcription factors plays a central role in the regulation of lymphocyte proliferation, differentiation and survival. Aberrant constitutive a ...

    STTRPhase I2010Department of Health and Human Services
  3. NF-kB Inhibition of Lung Ischemia Repurfusion Injury

    Amount: $255,627.00

    DESCRIPTION (provided by applicant): Ischemia-reperfusion injury (IRI) is a major problem in many clinical scenarios, including myocardial infarction and stroke. IRI is also a major problem in organ t ...

    STTRPhase I2009Department of Health and Human Services
  4. Inhibition of IkK to treat lethal Graft-vs.-Host Disease

    Amount: $885,556.00

    DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, th ...

    STTRPhase II2008Department of Health and Human Services
  5. Blockade of NF-kappaB for Prevention/Treatment of GVHD

    Amount: $244,488.00

    DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, the ...

    STTRPhase I2006Department of Health and Human Services
  6. Validation of a Novel NF-KB Inhibitor in Murine IBD

    Amount: $216,950.00

    DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC), affect over one million Americans. Until recently, therapies for th ...

    STTRPhase I2006Department of Health and Human Services
  7. Validation of a Novel NF-KB Inhibitor in Murine IBD

    Amount: $216,950.00

    DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC), affect over one million Americans. Until recently, therapies for th ...

    SBIRPhase I2006Department of Health and Human Services
  8. Blockade of NF-kappaB for Prevention/Treatment of GVHD

    Amount: $244,488.00

    DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, the ...

    SBIRPhase I2006Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government